960298-00-4|2-(Benzyloxy)-4-bromopyridine| Ambeed

Structure of 960298-00-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 960298-00-4 ] Purity: 98% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 960298-00-4 ]

CAS No. :	960298-00-4
Formula :	C₁₂H₁₀BrNO
M.W :	264.12
SMILES Code :	BrC1=CC(OCC2=CC=CC=C2)=NC=C1
MDL No. :	MFCD13190654
InChI Key :	ZBTZIRNIUHLSSJ-UHFFFAOYSA-N
Pubchem ID :	53217389

Safety of [ 960298-00-4 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H332-H335
Precautionary Statements:	P261-P280-P305+P351+P338

Computational Chemistry of [ 960298-00-4 ] Show Less

Physicochemical Properties

Num. heavy atoms	15
Num. arom. heavy atoms	12
Fraction Csp3	0.08
Num. rotatable bonds	3
Num. H-bond acceptors	2.0
Num. H-bond donors	0.0
Molar Refractivity	62.92
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	22.12 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.79
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	3.34
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	3.27
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	2.83
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	3.52
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	3.15

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-3.98
Solubility	0.0279 mg/ml ; 0.000106 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-3.48
Solubility	0.0871 mg/ml ; 0.00033 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-5.54
Solubility	0.00076 mg/ml ; 0.00000288 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Moderately soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	Yes
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	Yes
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	Yes
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-5.54 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	0.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<0.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	2.11

Application In Synthesis of [ 960298-00-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 960298-00-4 ]

[ 960298-00-4 ] Synthesis Path-Downstream 1~35

1
4-bromo-2-hydroxy pyridine [ No CAS ]
[ 100-39-0 ]
[ 960298-00-4 ]

Yield	Reaction Conditions	Operation in experiment
	With silver carbonate; In benzene; at 55℃;Absence of light;	Example 22; ralphac-(35',4i?)-4-[2-(benzyloxy)pyridin-4-yl]-iV-cyclopropyl-4-hydroxy-iV-[3-(2-methoxyethoxy)-5- (3 -methoxypropyl)benzyl]piperidine-3 -carboxamide; Step 1 : 2-(benzyloxy')-4-bromopyridine; A flame-dried round bottom was charged with 4-bromopyridin-2-ol (1 eq.), benzene (0.14 M), Ag2CO3 (0.6 eq.) and benzyl bromide (1.2 eq.) under N2. The reaction was heated to 55 0C overnight in the dark. The reaction was then cooled and filtered, washing with dichloromethane. The filtrate was concentrated in vacuo and the residue was purified by flash chromatography (SiO2; 2-4% Et2O in hexanes) to give the desired product as a clear oil.; Example 44; i?flc-(3S,4R)-4-(l-butyl-2-oxo-l,2-dihydropyridin-4-yl)-N-cyclopropyl-4-methoxy-N-[3-(2- methoxyethoxy)-5 -(3 -methoxypropyl)berizyl]piperidme-3 -carboxamide; Step 1 : 2-(benzyloxy)-4-bromopyridine; A flame-dried round-bottom flask was charged with 4-bromo-2-pyridinol (1 eq.) benzene (0.14 M solution), Ag2CO3 (0.6 eq) and benzyl bromide (1.2 eq.) and heated to 55 0C in the dark for 15 h. The reaction mixture was cooled to rt, filtered through celite, washing with <n="61"/>CH2Cl2, and the filtrate concentrated in vacuo. The residue was purified by flash chromatography (SiO2; 2-4% Et2O in hexanes) to afford the title compound as a clear, colorless oil.

References: [1]Patent: WO2009/70869,2009,A1 .Location in patent: Page/Page column 43; 59-60.

2
[ 960298-00-4 ]
[ 1160185-08-9 ]
rac-tert-butyl (3S,4R)-4-[2-(benzyloxy)pyridin-4-yl]-3-({cyclopropyl[3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl]amino}carbonyl)-4-hydroxypiperidine-1-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		Step 2: rac-tert-bxxtv (3£4i?V4-r2-fbeiizyloxy)pyridin-4-yll-3-('{cvclopropyir3-(2- methoxyethoxy)-5-(3-methoxypropyl)benzyll amino } carbonyl)-4-hydroxypiperidine- 1 - carboxylate; To a solution of <strong>[960298-00-4]2-(benzyloxy)-4-bromopyridine</strong> from the previous step (1 eq.) inTHF (0.1M) at -78 0C was added n-BuLi (2.5 M in hexanes, 2.1 eq.). The mixture was stirred for30 min at -78 0C. MgBr2 (solid, 2.5 eq.) was added, and the resulting mixture stirred at -78 0C for 20 min, and 30 min at 0 0C. A solution of ketoamide 3.1 in THF (0.04 M) was added and the resulting mixture stirred at 0 0C for Ih and rt for 0.5 h. The reaction was quenched with saturated aqueous NH4Cl solution and extracted 2 x Et2O. The combined organic extracts were washed with brine, dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by automated flash chromatography (SiO2; 0-15% acetone in toluene) to afford the title compound as a clear colorless oil.
		Step 2: mc-tert-butyl O£4i?V4-r2-(benzyloxy)pyridin-4-yl1-3-alphacvclopropyP-(2- methoxyethoxyV 5-(3 -methoxypropyDbenzyl] amino ) carbonylM-hydroxypiperidine- 1 - carboxylate; To a solution of the title compound from step 1 (1.47 eq.) in THF (0.3 M) at -78 0C was added n-BuLi (2.5 M in hexanes, 1.6 eq.). The resulting solution was stirred at -78 0C for 30 min. MgBr2 (0.5 M in Et2O, 1.9 eq.) was added, and the resulting solution was stirred at -78 0C for 30 min. A solution of ketoamide 3.1 (0.1 M in THF, 1 eq.) was added, and the reaction mixture warmed to rt over 16 h, quenched with NaHCO3 (aq., sat.), extracted with 2 x EtOAc. The combined organic phases were washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The residue was purified by automated flash chromatography (SiO2; 10- 80% EtOAc in hexanes) to afford the title compound as a clear, colorless oil.

References: [1]Patent: WO2009/70869,2009,A1 .Location in patent: Page/Page column 43.
[2]Patent: WO2009/70869,2009,A1 .Location in patent: Page/Page column 60.

3
[ 128071-98-7 ]
[ 100-51-6 ]
[ 960298-00-4 ]

Yield	Reaction Conditions	Operation in experiment
99%	With potassium tert-butylate; In tetrahydrofuran; at 0℃;Inert atmosphere;	Example 19i2-(Benzyloxy)-4-bromopyridine4-Bromo-2-fluoropyridine (5.28 g, 30 mmol) and benzyl alcohol (3.24 g, 30.00 mmol) were dissolved in dry THF (50 mL) under an atmosphere of argon. The solution was cooled with an external ice/water bath and held at 0 0C. Potassium tert-butoxidc (3.37 g, 30.00 mmol) was added in portions (approx. 100 mg each) under efficient stirring over a period of 20 min. Stirring at 0 0C was continued for 60 min, whereafter the cooling bath was removed and the mixture was stirred at rt for 30 min. Water (5 mL) was added to the reaction mixture and most of the THF was evaporated under reduced pressure. The remaining mixture was partitioned between pentane (75 mL) and water (50 mL). The organic phase was separated, washed with water (2x25 mL), dried over MgSO4 and the solvents removed in vacuo to afford 7.86 g (99%) of the title compound.1H NMR (500 MHz, DMSO-J6) delta 8.10 (d, IH) 7.44 (d, 2H) 7.38 (t, 2H) 7.33 (t, IH) 7.25 (d, IH) 7.20 (s, IH) 5.36 (s, 2H).
	dibenzo-18-crown-6; In toluene; for 3h;Dean-Stark conditions; Reflux;	Arene 1; 2-(Benzyloxy)-4-bromopyridine; To a solution of 4-bromo-2-fluoropyridine (1 eq.), benzyl alcohol (1.2 eq.) and dibenzo-18-crown-6 (0.05 eq.) in toluene (0.4 M) was added potassium hydroxide (2 eq.). A Dean-Stark apparatus was then attached and the reaction suspension was heated at reflux for 3 h. After cooling to RT, the reaction mixture was diluted with hexanes and then filtered through a pad of celite. Concentration of the filtrate in vacuo afforded a yellow oil. Purification of the crude product thus obtained by way of column chromatography (SiO2, 97:3 (v/v) Hex : Et2O) afforded the title compound as a colorless oil.
	With potassium hydroxide;dibenzo-18-crown-6; In toluene; for 3h;Inert atmosphere; Reflux;	To a solution of 4-bromo-2-fluoropyridine (1 eq.), benzyl alcohol (1.2 eq.) and dibenzo-18-crown-6 (0.05 eq.) in toluene (0.4 M) was added potassium hydroxide (2 eq.). A Dean-Stark apparatus was then attached and the reaction suspension was heated at reflux for 3 h. After cooling to RT, the reaction mixture was diluted with hexanes and then filtered through a pad of celite. Concentration of the filtrate in vacuo afforded a yellow oil. Purification of the crude product thus obtained by way of column chromatography (SiO2, 97:3 (v/v) Hex : Et2O) afforded the title compound as a colorless oil.

References: [1]Patent: WO2011/2409,2011,A1 .Location in patent: Page/Page column 37.
[2]Patent: WO2010/66028,2010,A1 .Location in patent: Page/Page column 28-29.
[3]Patent: WO2009/135299,2009,A1 .Location in patent: Page/Page column 108.

4
[ 960298-00-4 ]
[ 1160185-08-9 ]
tert-butyl trans-4-[2-(benzyloxy)-4-pyridinyl]-3-({cyclopropyl[3-(2-methoxyethoxy)-5-(3-methoxypropyl)benzyl]amino}carbonyl)-4-hydroxy-1-piperidinecarboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		Step 2: tert-Butyl tralphan5-4-[2-(benzyloxy)-4-pyridinyl]-3-({cyclopropyl[3-(2-methoxyethoxy)-5- (3 -methoxypropyl)benzyl] amino } carbonyl)-4-hydroxy- 1 -piperidinecarboxylate; To a THF solution (0.08 M) of Arene 1 was added at -780C rc-butyl lithium (2.5 M solution in hexanes, 2.1 eq.). After stirring at -780C for 30 min, solid magnesium bromide (2.5 eq.) was added in one rapid portion and the resulting mixture was stirred at -780C for 20 min. The reaction mixture was then slowly warmed to O0C over 30 min and f°rt-butyl 3- ( { cyclopropyl [3 -(2-methoxyethoxy)-5 -(3 -methoxypropyl)ben:zyl] amino } carbonyl)-4-oxo- 1 - piperidinecarboxylate (1 eq.) from the previous step was added as a THF solution. The reaction mixture was then stirred at O0C for 1 h and at RT for 30 min. The reaction was then quenched with the addition of sat. aq. NH4Cl and ether. The aqueous layer was separated and back- extracted with ether. The combined organic extracts were washed further with brine, dried over MgSO4, filtered and the filtrate concentrated in vacuo. Purification of the crude product thus obtained by way of column chromatography (SiO2, 96:4 -> 93:7 (v/v) acetone: toluene) afforded the title compound.

References: [1]Patent: WO2010/66028,2010,A1 .Location in patent: Page/Page column 31.

5
[ 36953-37-4 ]
[ 100-39-0 ]
[ 960298-00-4 ]

Yield	Reaction Conditions	Operation in experiment
	With silver carbonate; In benzene; at 20 - 50℃; for 40h;Protection from light;	A mixture of 4-Bromo-1H-pyridin-2-one (0.613 g), silver carbonate (0.63 g) and benzyl bromide (0.50 mL) in benzene (10 mL) was heated at 50C for 24 hours, protected from light. Reaction mixture stirred ambient temperature for 16 hours. Reaction mixture was filtered through a pad of CELITE, which was washed ethyl acetate. The filtrate was concentrated and purified by flash column chromatography (silica gel, 0 to 10% ethyl acetate/hexanes) to give 2-Benzyloxy-4-bromo-pyridine (0.6043 g): LCMS-ESI+: calc'd for C12H11BrNO: 265.12 (M+H+); Found: 263.8, 265.8 (M+H+).

References: [1]Patent: WO2010/132601,2010,A1 .Location in patent: Page/Page column 467.

6
[ 960298-00-4 ]
[ 1341204-97-4 ]
2-(5-(4-(2-benzyloxypyridin-4-yl)phenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With potassium carbonate;tetrakis(triphenylphosphine) palladium(0); In 1,2-dimethoxyethane; water; at 80 - 90℃; for 8h;	A mixture of 2-Benzyloxy-4-bromo-pyridine (0.292 g), 2-{5-[4-(4,4,5,5- Tetramethyl-(1,3,2)-ldioxaborolan-2-yl)-phenyl)-1H-imidazol-2-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester (0.533 g, prepared according to WO2008021927 A2) and Pd(PPh3)4 (0.064 g) in aq. K2CO3 solution/dimethoxyethane (1.82 mL/5.0 mL) was heated at 80-90C for 8 hours. Reaction mixture was cooled, diluted with ethyl acetate, washed with brine, dried (MgSO4) and concentrated. The residue was purified by flash column chromatography (silica gel, 20 to 80% ethyl acetate/hexanes) to give 2-{5-[4-(2-Benzyloxy-pyridin-4-yl)-phenyl]-1H-imidazol-2-yl}- pyrrolidine-1-carboxylic acid tert-butyl ester (0.530 g): LCMS-ESI+: calc'd for C30H33N4O3: 497.6 (M+H+); Found: 497.0 (M+H+).

References: [1]Patent: WO2010/132601,2010,A1 .Location in patent: Page/Page column 467-468.

8
[ 248270-00-0 ]
[ 960298-00-4 ]
[ 1423175-51-2 ]

Yield	Reaction Conditions	Operation in experiment
0.3 g	With tetrakis(triphenylphosphine) palladium(0); potassium carbonate; In 1,4-dioxane; water; for 6h;Reflux;	(2) A mixed solution comprising 0.28 g of <strong>[960298-00-4]2-(benzyloxy)-4-bromopyridine</strong>, 0.28 g of (2-fluoro-4-methyl-5-((2,2,2-trifluoroethyl)thio)phenyl)boronic acid, 0.060 g of tetrakis(triphenylphosphine)palladium, 0.29 g of potassium carbonate, 2 mL of 1 ,4- dioxane and 2 mL of water, was heated and refluxed for 6 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. Then, the organic layer was washed with water and an aqueous sodium chloride solution, and anhydrous sodium sulfate was added for drying. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: n- heptane/ethyl acetate=15/1) to obtain 0.30 g of the oily desired product.

References: [1]Patent: WO2013/27660,2013,A1 .Location in patent: Page/Page column 23.

9
[ 73583-37-6 ]
[ 100-51-6 ]
[ 960298-00-4 ]

Yield	Reaction Conditions	Operation in experiment
46.3%		To a solution of phenylmethanol (2.248 g, 20.79 mmol) in THF (100 mL), was added NaH (60% w/w) (0.914 g, 22.86 mmol) at 0C. The reaction mixture was stirred at 0C for 4 hr. 4-bromo-2- chloropyridine (2 g, 10.39 mmol) in THF (50 mL) was added dropwise into the reaction mixture at 0 C. The reaction mixture was stirred at 25C for overnight. The reaction mixture was partitioned between EtOAc (100 mL) and water (100 mL). The organic phase was washed with saturated brine (100 mL), dried over sodium sulphate and evaporated in vacuo to give the crude product. The crude product was purified by Combi-Flash chromatography on a silica column (24g) and eluted with EtOAc/petroleum (0-100% over 10 min, 100% over 5 min). Appropriate fractions were evaporated to give the title compound (1.272 g, 4.82 mmol, 46.3 % yield) as a white oil. LCMS: MH+ =264/266
0.71 g		(1) 0.37 g of sodium hydride was added to a mixed solution comprising 1.1 g of benzyl alcohol and 3 mL of tetrahydrofuran while cooling with an ice bath, followed by stirring at room temperature for 10 minutes. A mixed solution comprising 0.60 g of 4- bromo-2-chloropyridine and 1 mL of tetrahydrofuran, was added to the reaction solution, followed by heating and refluxing for 3 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. Then, the organic layer was washed with water and an aqueous sodium chloride solution, and anhydrous sodium sulfate was added for drying. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: n- heptane/ethyl acetate=10/1) to obtain 0.71 g of oily 2-(benzyloxy)-4-bromopyridine.

References: [1]Patent: WO2014/78257,2014,A1 .Location in patent: Page/Page column 129.
[2]Patent: WO2013/27660,2013,A1 .Location in patent: Page/Page column 23.

10
[ 960298-00-4 ]
[ 1423175-52-3 ]

References: [1]Patent: WO2013/27660,2013,A1 .

11
[ 960298-00-4 ]
(1,1,2,2,2-pentafluoroethyl)(1,10-phenanthroline-κΝ1,κN10)-copper [ No CAS ]
[ 1580464-70-5 ]

References: [1]Organic Letters,2014,vol. 16,p. 1744 - 1747.

12
[ 36953-37-4 ]
[ 100-39-0 ]
[ 960298-00-4 ]
1-benzyl-4-bromopyridin-2(1H)-one [ No CAS ]

References: [1]Organic Letters,2015,vol. 17,p. 3382 - 3385.

13
2-(benzyloxy)pyridin-4-amine [ No CAS ]
[ 960298-00-4 ]
2-benzyloxy-3,4-dibromopyridine [ No CAS ]
2-benzyloxy-3,4,5-tribromopyridine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
62%; 13%; 12%	With tert.-butylnitrite; copper(ll) bromide; In acetonitrile; at 20℃; for 16h;	To a solution of CuBr2 (536 mg, 2.4 mmol) in acetonitrile (6 mL) was addedtBuONO (356 muL, 3.0 mmol) and the mixture was stirred for 15 min. A solution of 2-benzyloxy-4-aminopyridine 6 (400.5 mg, 2.0 mmol) in acetonitrile (4 mL) was addedand the mixture was stirred for 16h. After concentration under reduced pressure, aq.15% ammonia solution was added and the aqueous layer was extracted with ethylacetate (3x). The combined organic layers were dried (Na2SO4), filtered andconcentrated under reduced pressure. Purification by flash chromatography on silicagel (hexane/DCM: 80/20) first yielded 2-benzyloxy-3, 4, 5-tribromopyridine 7c (97mg, 12%) as a colorless solid.

References: [1]Synlett,2016,vol. 27,p. 67 - 69.

14
[ 960298-00-4 ]
[ 36953-37-4 ]

Yield	Reaction Conditions	Operation in experiment
82%	With hydrogenchloride; In methanol;Reflux;	To a solution of <strong>[960298-00-4]2-benzyloxy-4-bromopyridine</strong> 6 (201 mg, 0.8 mmol) in MeOH(4.5 mL) was added conc. HCl (2.3 mL). The mixture was heated at reflux overnight.Then the reaction mixture was cooled to room temperature and concentrated underreduced pressure. The residue was poured into cold water and carefully quenchedwith aq. sat. Na2CO3. The aqueous layer was extracted with ethyl acetate (3x). Thecombined organic layers were washed with brine, dried (Na2SO4), filtered andconcentrated under reduced pressure. The crude was purified by flash chromatography on silica gel (EtOAc/MeOH: 98/2) to give 1c (109 mg, 82%) as acolorless solid. Data for 1c are reported above.

References: [1]Synlett,2016,vol. 27,p. 67 - 69.

15
[ 14432-12-3 ]
[ 960298-00-4 ]

References: [1]Synlett,2016,vol. 27,p. 67 - 69.

16
[ 100-51-6 ]
[ 960298-00-4 ]
2-benzyloxy-3,4-dibromopyridine [ No CAS ]
2-benzyloxy-3,4,5-tribromopyridine [ No CAS ]

References: [1]Synlett,2016,vol. 27,p. 67 - 69.

17
[ 960298-00-4 ]
C₂₃H₂₂N₄ [ No CAS ]
4-(4-cyclopropyl-3-(4-(2-oxo-1,2-dihydropyridin-4-yl)piperazin-1-yl)quinolin-8-yl)benzonitrile [ No CAS ]

References: [1]Patent: EP3124482,2017,A1 .

18
[ 960298-00-4 ]
C₂₃H₂₂N₄ [ No CAS ]
C₃₅H₃₁N₅O [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
65.93%	With tris-(dibenzylideneacetone)dipalladium(0); 4,5?-bis(diphenylphosphino)-9,9?-dimethylxanthene; potassium tert-butylate; In toluene; at 110℃; for 2h;Inert atmosphere;	Step 1: Under nitrogen gas atmosphere, Pd2(dba)3 (38.75 mg, 42.32 mumol) was added into a mixture of 271-1 (150 mg, 423.19 mumol), sodium tert-butoxide (81.34 mg, 846.38 mumol), Xantphos (48.97 mg, 84.64 mumol) and 271-2 (134.13 mg, 507.83 mumol) in toluene (10 mL). The mixture was stirred at 110C for 2h, poured into H2O (150 mL). The obtained mixture was extracted with EtOAc (100×3). The organic phases were combined and washed with brines (100 mL), dried over anhydrous sodium sulfate, filtrated, and concentrated under vacuum. The residue was purified by column chromatography (PE/EtOAc=3:1) to deliver 271-3 (150 mg, yield 65.93%) as yellow solid. MS ESI calcd for C35H31N5O [M+H]+ 538, found 538.

References: [1]Patent: EP3124482,2017,A1 .Location in patent: Paragraph 0718; 0719.

19
[ 960298-00-4 ]
tert-butyl (1R,5R)-8-oxo-10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,5,6,8-tetrahydro-2H-1,5-methanopyrido[1,2-a][1,5]diazocine-3(4H)-carboxylate [ No CAS ]
(-)-N-Boc-(4-(2-benzyloxy)pyridine)cytisine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With bis-triphenylphosphine-palladium(II) chloride; caesium carbonate; In tetrahydrofuran; at 80℃; for 48h;	A/-Boc-4-(4,4,5,5-Tetramethyl-1 ,3,2,-dioxaborolan-2-yl)-cytisine 58 was made following the genenal procedure for the borylation of cytisine detailed above in Example 1 in a 1 .00 mmol scale. (0357) Anhydrous Cs2C03 (814 mg, 2.5 mmol) and PdCI2(PPh3)2 (35 mg, 5 mol%) were added over the crude borylation reaction mixture. Dry THF (5.0 mL) was added followed by a solution of <strong>[960298-00-4]4-bromo-2-benzyloxypyridine</strong> (316 mg, 1 .2 mmol) in dry THF (5.0 mL). The mixture was stirred at 80 C for 48 h. The solution was cooled to r.t., diluted with EtOAc (50 mL) and filtered through Celite. The organic layer was washed with water (10 mL), brine (10 mL), dried over Na2S04, filtered and concentrated in vacuo. The crude reaction mixture was purified by flash column chromatography on silica gel [DCM/MeOH (4% MeOH)+ 0.1 % ammonia (15% aq. sol.)] to give 105 (485 mg, 99%) with few impurities as a pale yellow oil. The product was used in the next step without any further purification. (0358) R/: 0.23 [DCM/MeOH (5% MeOH)]; 1H NMR (400 MHz, CDCI3, deltaEta): 8.22 (d, 1 H, J = 5.0 Hz, C16-H), 7.46 (d, 2H, J = 7.0 Hz, C20-H, C24-H), 7.39-7.29 (m, 3H, C21 -H, C22-H, C23-H), 7.04 (d, 1 H, J= 5.0 Hz, C17-H), 6.96 (s, 1 H, C14-H), 6.67 (s, 1 H, C3-H), 6.27 (s, 1 H, C5-H), 5.41 (s, 2H, C18-H), 4.40-4.18 (m, 3H, C7-Ha, C1 1 -H, C12-H), 3.84 (dd, 1 H, J = 6.5, 15.5 Hz, C7-Hb), 3.05 (s, 3H, C10-H, C1 1 -H, C12-H), 2.44 (s, 1 H, C8-H), 2.03-1 .94 (m, 2H, C9-H), 1 .33-1 .17 (m, 9H, Boc); 13C NMR (100 MHz, CDCI3, 5C): 164.4 (C15), 163.4 (CO), 154.7/154.4 (CO Boc, rotamers), 150.0, 149.5 (C6, C4), 148.3, 147.7 (C13, C16), 137.2 (C19), 128.6, 128.1 , 128.0 (5C, C20, C21 , C22, C23, C24), 1 14.9, 1 14.5 (C3, C17), 108.9/108.7 (C14, rotamers), 104.4/103.7 (C5, rotamers), 80.5/79.9 (q Boc, rotamers), 68.0 (C18), 51 .8/50.7/50.5/49.4 (C1 1 , C12, rotamers), 49.0 (C7), 35.3 (C10), 28.2 (3C, Boc), 27.6 (C8), 26.3 (C9); HRMS (ESI+): calculated for C28H32N3O4: 474.2387, found [M+H]+: 474.2383, calculated for C28H3i N3Na04: 496.2207, found [M+Na]+: 496.2198.

References: [1]Patent: WO2018/33742,2018,A2 .Location in patent: Page/Page column 57-58.

20
[ 960298-00-4 ]
2-(5-(4-(2-oxo-1,2-dihydropyridin-4-yl)phenyl)-1-(2-trimethylsilanylethoxymethyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester [ No CAS ]

References: [1]Patent: WO2010/132601,2010,A1 .

21
[ 960298-00-4 ]
2-(5-(4-(2-benzyloxypyridin-4-yl)phenyl)-1-(2-trimethylsilanylethoxymethyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester [ No CAS ]

References: [1]Patent: WO2010/132601,2010,A1 .

22
[ 960298-00-4 ]
2-(4-(4-(4-(2-(1-tert-butoxycarbonylpyrrolidin-2-yl)-3-(2-trimethylsilanylethoxymethyl)-3H-imidazol-4-yl)phenyl)-2-oxo-2H-pyridin-1-yl)-1-(3-trimethylsilanylethoxymethyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester [ No CAS ]

References: [1]Patent: WO2010/132601,2010,A1 .

23
[ 960298-00-4 ]
(1-(2-(5-(4-(4-(2-(1-(2-methoxycarbonylamino-3-methylbutyryl)pyrrolidin-2-yl)-3H-imidazol-4-yl)phenyl)-2-oxo-2H-pyridin-1-yl)-1H-imidazol-2-yl)pyrrolidine-1-carbonyl)-2-methylpropyl)carbamic acid methyl ester bis(trfluoroacetate) [ No CAS ]

References: [1]Patent: WO2010/132601,2010,A1 .

24
[ 960298-00-4 ]
2-(2-(benzyloxy)pyridin-4-yl)-6-chloro-1H-pyrrolo[2,3-b]pyridine [ No CAS ]